RBC Capital Calls XOMA's (XOMA) '358 'Sleeper Candidate'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting
March 7, 2015 4:05 PM EST- Results show XOMA 358 reduces insulin receptor signaling and increased glucose production after exogenous insulin injection
- XOMA 358 shows potential for treatment of hyperinsulinemic hypoglycemia conditions
BERKELEY, Calif., March 7, 2015 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from XOMA 358, the lead antibody in the Company's XMet D program, today, at the Endocrine Society's Annual Meeting ENDO 2015. Paul Rubin, M.D., Senior Vice President, Research and Development, and Chief Medical Officer at XOMA, presented the Company's data, titled "XOMA 358, a Novel... More
